RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx to Participate at Investor Conferences in March

44th Annual Cowen Healthcare Conference on March 4

Leerink Partners Global Biopharma Conference on March 12

Barclays 26th Annual Global Healthcare Conference on March 13

NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) --  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.

44th Annual Cowen Healthcare Conference (Boston, MA)

  • Monday, March 4, 2024, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings.

Leerink Partners Global Biopharma Conference (Miami, FL)

  • Tuesday, March 12, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.

Barclays 26th Annual Global Healthcare Conference (Miami, FL)

  • Wednesday, March 13, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1x1 meetings.

The live and archived webcast of the fireside chat will be accessible from the company’s website at .

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: .

Contacts – Ultragenyx

Investors

Media



EN
27/02/2024

Underlying

RAREUltragenyx Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultragenyx Pharmaceutical Inc.

David Carlson ... (+8)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
SRPT SAREPTA THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
ARDX ARDELYX INC
UTHR UNITED THERAPEUTICS CORPORATION
GTHX G1 THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
23h / 28m 23h / 28m 1 EN
 PRESS RELEASE
Free
RARE Ultragenyx Phar...

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Re...

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024. The live and replayed webcast of the call will be available through ...

April 25, 2024 1 EN
 PRESS RELEASE
Free
RARE Ultragenyx Phar...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan...

April 19, 2024 1 EN
Wedbush Research
  • Wedbush Research
TPX TEMPUR SEALY INTERNATIONAL INC
2454 MEDIATEK INC.
VMW VMWARE INC. CLASS A
ADS ADIDAS AG
WDC WESTERN DIGITAL CORPORATION
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
BIIB BIOGEN INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
SNBR SLEEP NUMBER CORPORATION
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
AVGO BROADCOM INC.
DELL DELL TECHNOLOGIES INC CLASS C
SMCI SUPER MICRO COMPUTER
TVTX INC.
MRVL TRAVERE THERAPEUTICS INC
STX MARVELL TECHNOLOGY INC
DBD SEAGATE TECHNOLOGY HLDGS PLC
DIEBOLD NIXDORF INC
04/17/24 April 17, 2024 1 EN
Laura Chico
  • Laura Chico
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
04/17/24 April 17, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch